You can buy or sell ALLO and other stocks, options, and ETFs commission-free!
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
David D. Chang
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected May 5, After Hours